Abstract
Activation of protein tyrosine kinases is prevalent in human cancers and previous studies have demonstrated that Stat3 signaling is a point of convergence for many of these tyrosine kinases. Moreover, a critical role for constitutive activation of Stat3 in tumor cell proliferation and survival has been established in diverse cancers. However, the oncogenic signaling pathways in melanoma cells remain to be fully defined. In this study, we demonstrate that Stat3 is constitutively activated in a majority of human melanoma cell lines and tumor specimens examined. Blocking Src tyrosine kinase activity, but not EGF receptor or JAK family kinases, leads to inhibition of Stat3 signaling in melanoma cell lines. Consistent with a role of Src in the pathogenesis of melanoma, we show that c-Src tyrosine kinase is activated in melanoma cell lines. Significantly, melanoma cells undergo apoptosis when either Src kinase activity or Stat3 signaling is inhibited. Blockade of Src or Stat3 is also accompanied by down-regulation of expression of the anti-apoptotic genes, Bcl-xL and Mcl-1. These findings demonstrate that Src-activated Stat3 signaling is important for the growth and survival of melanoma tumor cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R . 2001 Proc. Natl. Acad. Sci. USA 98: 7319–7324
Bowman T, Garcia R, Turkson J, Jove R . 2000 Oncogene 19: 2474–2488
Bromberg J, Darnell Jr JE . 2000 Oncogene 19: 2468–2473
Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell Jr JE . 1998 Mol. Cell. Biol. 18: 2553–2558
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell Jr JE . 1999 Cell 98: 295–303
Buettner R, Mora LB, Jove R . 2002 Clin. Cancer Res. 8: 945–954
Catlett-Falcone R, Dalton WS, Jove R . 1999a Curr. Opin. Oncol. 11: 490–496
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R . 1999b Immunity 10: 105–115
Ciardiello F, Tortora G . 2001 Clin. Cancer Res. 7: 2958–2970
Dorsey JF, Jove R, Kraker AJ, Wu J . 2000 Cancer Res. 60: 3127–3131
Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, LI Y, Wang JM, Yang-Yen HF, Karras J, Jove R, Loughran TPJ . 2001 J. Clin. Invest. 107: 351–362
Fry DW . 1999 Pharmacol. Ther. 82: 207–218
Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R . 2001 Oncogene 20: 2499–2513
Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, Fujita DJ, Ethier SP, Jove R . 1997 Cell Growth Differ. 8: 1267–1276
Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ . 1998 J. Clin. Invest. 102: 1385–1392
Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD . 2000 Proc. Natl. Acad. Sci. USA 97: 4227–4232
Huang M, Dorsey JF, Epling-Burnette PK, Landowski TH, Mora LB, Niu G, Sinibaldi D, Nimmanapalli R, Bai F, Kraker A, Yu H, Moscinski L, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R . 2002 Oncogene, in press
Irby RB, Yeatman TJ . 2000 Oncogene 19: 5636–5642
Karni R, Jove R, Levitzki A . 1999 Oncogene 18: 4654–4662
Kraker AJ, Hartl BG, Amar AM, Barvian MR, Showalter HD, Moore CW . 2000 Biochem. Pharmacol. 60: 885–898
Laudano AP, Buchanan JM . 1986 Proc. Natl. Acad. Sci. USA 83: 892–896
Levitzki A . 1999 Pharmacol. Ther. 82: 231–239
Mendelsohn J, Baselga J . 2000 Oncogene 19: 6550–6565
Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM . 1996 Nature 379: 645–648
Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N . 1999 Cancer Res. 59: 6145–6152
Ni Z, Lou W, Leman ES, Gao AC . 2000 Cancer Res. 60: 1225–1228
Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R, Yu H . 1999 Cancer Res. 59: 5059–5063
Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, Jove R, Yu H . 2001 Cancer Res. 61: 3276–3280
Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H . 2002 Oncogene 21: 2000–2008
Reddy EP, Korapati A, Chaturvedi P, Rane S . 2000 Oncogene 19: 2532–2547
Shen Y, Devgan G, Darnell Jr JE, Bromberg JF . 2001 Proc. Natl. Acad. Sci. USA 98: 1543–1548
Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R . 2000 Oncogene 19: 5419–5427
Song JI, Grandis JR . 2000 Oncogene 19: 2489–2495
Staley CA, Parikh NU, Gallick GE . 1997 Cell Growth Differ. 8: 269–274
Turkson J, Bowman T, Garcia R, Caldenhoven E, de Groot RP, Jove R . 1998 Mol. Cell. Biol. 18: 2545–2552
Turkson J, Jove R . 2000 Oncogene 19: 6613–6626
Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton AD, Jove R . 2001 J. Biol. Chem. 276: 45443–45455
Wagner BJ, Hayes TE, Hoban CJ, Cochran BH . 1990 EMBO J. 9: 4477–4484
Yayon A, Ma Y-S, Safran M, Klagsbrun M, Halaban R . 1997 Oncogene 14: 2999–3009
Yu CL, Meyer D, Campbell GS, Larner AC, Carter-Su C, Schwartz J, Jove R . 1995 Science 269: 81–83
Zhou P, Qian L, Kozopas KM, Craig RW . 1997 Blood 89: 630–643
Acknowledgements
This work was supported by National Institutes of Health Grants (CA75243, CA89693, CA55652 and CA82533) and by the Dr Tsai-Fan Yu Cancer Research Endowment. We thank Drs George Blanck and Suzanne Topalian for melanoma cell lines, Andy Laudano for phospho-Src antibodies, Anita Larson for assisting with preparation of the manuscript. This work was supported in part by the Flow Cytometry Core Facility, Statistical Core Facility, Clinical Trials Facility, Translational Research Laboratory and Image Core Facility at the H Lee Moffitt Cancer Center & Research Institute.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Niu, G., Bowman, T., Huang, M. et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21, 7001–7010 (2002). https://doi.org/10.1038/sj.onc.1205859
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205859
Keywords
This article is cited by
-
The mechanism and consequences of BRAF inhibitor resistance in melanoma
Genome Instability & Disease (2023)
-
Nitric-Oxide Synthase trafficking inducer (NOSTRIN) is an emerging negative regulator of colon cancer progression
BMC Cancer (2022)
-
Current understanding of epigenetics role in melanoma treatment and resistance
Cancer Cell International (2022)
-
Ciclopirox drives growth arrest and autophagic cell death through STAT3 in gastric cancer cells
Cell Death & Disease (2022)
-
STAT3 transcription factor as target for anti-cancer therapy
Pharmacological Reports (2020)